Cretostimogene treatment shows best-in-class durability of response for BCG-unresponsive non-muscle invasive bladder cancer ...

Learn more about the role of Tuberculosis in cancer and how a simple vaccine supports the immune system to fight it.

Analysts at HC Wainwright lowered their Q1 2025 EPS estimates for shares of CG Oncology in a research report issued to clients and investors on Monday, March 31st. HC Wainwright analyst A. Maldonado ...

Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) - - Initiated CORE-008 ...

Following surgery to remove the tumor, bladder cancer patients are typically given a live Bacillus Calmette Guerin (BCG) ...

Cretostimogene is an oncolytic immunotherapy with dual mechanism of action: viral replication leading to tumor lysis and release of granulocyte-macrophage colony stimulating factor.

The promotional effort from Ferring features bladder cancer survivors sharing the news of a new treatment option.

The company’s Phase I trial found that patients remained disease free after three months utilising the lowest doses of RAG-01 ...

Immunotherapy is an innovative way to harness the power of the body’s immune system to fight threats like cancer. Normally, our immune system can detect and destroy abnormal cells on its own. But when ...

NDV-01 is a novel, sustained-release, intravesical gemcitabine/docetaxel, ready-for-use product candidate for the treatment of non-muscle ...